Start here if you're new
what it is
Actuate is a clinical-stage cancer drug company developing elraglusib for hard-to-treat tumors.
how it gets paid
Last year Actuate Therapeutics made n/a in revenue. Elraglusib clinical development was the main engine at $0M, or 100% of sales.
what just happened
In the latest filed quarter (Q3 2025, period ended Sept. 30, 2025), diluted loss was $(0.25) per share; for the nine months ended that date, diluted loss was $(0.88) per share. Still no product revenue.
At a glance
n/a balance sheet
pre-revenue — trailing p/e not meaningful
clinical-stage — losses funded by cash on hand
~$60M market cap
What they do
Actuate is a clinical-stage cancer drug company developing elraglusib for hard-to-treat tumors.
The moat is science, not scale. Elraglusib is a GSK-3β inhibitor, which means it blocks a cancer signaling enzyme. So what: the whole thesis hangs on one pathway and one randomized Phase 2 trial in mPDAC. If that trial works, you own a story with 10 employees behind it. If it fails, you own a small biotech with $0M revenue and $0M debt.
How they make money
$0
annual revenue (pre-revenue)
Elraglusib clinical development
$0M
mPDAC randomized Phase 2
$0M
Oral tablet Phase 1/2 program
$0M
Corporate overhead
$0M
The products that matter
oncology drug candidate
elraglusib
Phase 1/2 · $60M valuation riding on it
It is the only clinical-stage asset named on this page, and the current $60M equity story rests on its Phase 1/2 results. You do not own a broad pipeline here. You own one lead shot on goal.
single asset
Key numbers
$(0.25)
Q3 2025 diluted EPS
$(0.88)
nine months 2025 diluted EPS
n/a
trailing p/e
n/a
dividend yield
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $0M (1% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ACTU right now.
source: institutional data · return history unavailable
What just happened
SEC filing
Q3 2025 (filed): $(0.25) diluted EPS; nine-month diluted loss $(0.88). Revenue still $0.
Per the Form 10-Q for the quarter ended Sept. 30, 2025: diluted net loss per share was $(0.25) for the quarter and $(0.88) for the nine months then ended. This is a clinical-stage name — the filing is about burn and balance sheet, not sales.
$0M
revenue
$(0.25)
Q3 2025 diluted EPS
$(0.88)
9M 2025 diluted EPS
how to read it
Do not mix up one quarter with nine months: $(0.88) is year-to-date in that filing, not a single quarter. Trailing P/E is not meaningful while revenue is zero.
snap-source: SEC Form 10-Q (quarter ended Sept. 30, 2025) — EDGAR 10-Q list
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The risk stack is unusually concentrated. One drug candidate carries the story, one cash-burn line can force dilution, and one soft readout can knock out most of the bull case at once.
med
trial data disappoints
The entire $60M valuation rests on Phase 1/2 evidence for elraglusib. Oncology failure rates are brutal, and early signals that look promising do not always survive more scrutiny.
a weak readout would pressure most of the current equity story at once
med
cash burn leads to dilution
This page already points to operating cash burn above $20M in FY2024. For a pre-revenue company with a ~$60M market cap, raising capital is never background noise. It can become the whole story.
new shares sold at the wrong price could dilute you hard before the science is proven
med
success still does not guarantee commercial value
Difficult-to-treat cancers attract serious money and serious competition. Even if elraglusib advances, ACTU would still need to prove differentiation, financing discipline, and a path to economic value.
the drug could work well enough to continue and still fall short of investor hopes
One failed asset would hit nearly 100% of the current story. One financing round at a weak price could reshape the cap table. That is the actual risk stack.
source: institutional data · regulatory filings · risk analysis
Pay attention to
core catalyst
next elraglusib Phase 1/2 update
This is the number that mattered yesterday and the number that will matter next. In a one-asset biotech, trial evidence moves the stock more than quarters of accounting noise.
calendar
Q4 2025 earnings and cash update
You want the cash position, burn trajectory, and any clue about how long management can fund development before tapping the market again.
risk
any financing before stronger data
With operating cash burn above $20M in FY2024, a raise before a cleaner efficacy signal would shift your focus from science to dilution fast.
sentiment
whether analyst targets start moving down to reality
486% implied upside looks dramatic. Here is the thing: in thin coverage, revisions matter more than the headline target because one model change can reset the whole mood.
Analyst rankings
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for ACTU is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive